BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 16754599)

  • 21. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience.
    Pavlov MJ; Kovacevic PA; Ceranic MS; Stamenkovic AB; Ivanovic AM; Kecmanovic DM
    Eur J Surg Oncol; 2009 Nov; 35(11):1186-91. PubMed ID: 19356887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weekly systemic cisplatin plus locoregional hyperthermia: an effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area.
    Franckena M; De Wit R; Ansink AC; Notenboom A; Canters RA; Fatehi D; Van Rhoon GC; Van Der Zee J
    Int J Hyperthermia; 2007 Aug; 23(5):443-50. PubMed ID: 17701535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan.
    Raspagliesi F; Kusamura S; Campos Torres JC; de Souza GA; Ditto A; Zanaboni F; Younan R; Baratti D; Mariani L; Laterza B; Deraco M
    Eur J Surg Oncol; 2006 Aug; 32(6):671-5. PubMed ID: 16621425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
    Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
    Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
    Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
    Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
    Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
    Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
    Bartlett DL; Buell JF; Libutti SK; Reed E; Lee KB; Figg WD; Venzon DJ; Alexander HR
    Cancer; 1998 Sep; 83(6):1251-61. PubMed ID: 9740093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.
    Fagotti A; Paris I; Grimolizzi F; Fanfani F; Vizzielli G; Naldini A; Scambia G
    Gynecol Oncol; 2009 Jun; 113(3):335-40. PubMed ID: 19345401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A feasibility study in oesophageal carcinoma using deep loco-regional hyperthermia combined with concurrent chemotherapy followed by surgery.
    Albregts M; Hulshof MC; Zum Vörde Sive Vörding PJ; van Lanschot JJ; Richel DJ; Crezee H; Fockens P; van Dijk JD; González González D
    Int J Hyperthermia; 2004 Sep; 20(6):647-59. PubMed ID: 15370820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma.
    Gelblum D; Mychalczak B; Almadrones L; Spriggs D; Barakat R
    Gynecol Oncol; 1998 Apr; 69(1):36-41. PubMed ID: 9570996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
    Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
    Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hyperthermia in combination with chemotherapy in gynecological cancers].
    Rietbroek RC; Schilthuis MS; van der Zee J; González González D
    Ned Tijdschr Geneeskd; 1999 Jan; 143(2):85-8. PubMed ID: 10086110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I/II trial of hyperfractionated accelerated chemoradiotherapy for unresectable advanced pancreatic cancer.
    Tsujie M; Nakamori S; Tanaka E; Nagano H; Umeshita K; Dono K; Sakon M; Inoue T; Inoue T; Monden M
    Jpn J Clin Oncol; 2006 Aug; 36(8):504-10. PubMed ID: 16855011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intraperitoneal cis-platinum as salvage therapy for refractory epithelial ovarian cancer.
    Hacker NF; Berek JS; Pretorius RG; Zuckerman J; Eisenkop S; Lagasse LD
    Obstet Gynecol; 1987 Nov; 70(5):759-64. PubMed ID: 3658287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after previous chemoradiation.
    Heijkoop ST; van Doorn HC; Stalpers LJ; Boere IA; van der Velden J; Franckena M; Westermann AM
    Int J Hyperthermia; 2014 Feb; 30(1):6-10. PubMed ID: 24156619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.